Article
PD-L1 expression, EGFR and KRAS mutations and survival among stage III unresected non-small cell lung cancer patients: a Danish cohort study.
Scientific reports - 19 Aug 2021
Cronin-Fenton Deirdre, Dalvi Tapashi, Movva Naimisha, Pedersen Lars, Hansen Hanh, Fryzek Jon, Hedgeman Elizabeth, Mellemgaard Anders, Rasmussen Torben R, Shire Norah, Hamilton-Dutoit Stephen, Nørgaard Mette
Abstract excerpt
Programmed cell death receptor ligand-1 (PD-L1) expression, KRAS (KRASm) and EGFR (EGFRm) mutations may influence non-small cell lung cancer (NSCLC) prognosis. We aimed to evaluate PD-L1 expression, KRASm, and EGFRm and survival among stage III unresected NSCLC patients. Using Danish registries, we collected data on stage III unresected NSCLC patients diagnosed 2001-2012 and paraffin-embedded tumor tissue from...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
